AbbVie (NYSE:ABBV) Price Target Raised to $270.00

AbbVie (NYSE:ABBV) had its price objective raised by Morgan Stanley from $269.00 to $270.00 in a report released on Thursday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

Several other brokerages have also recently issued reports on ABBV. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research report on Monday, November 3rd. Evercore decreased their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday. Citigroup cut their target price on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Finally, HSBC raised AbbVie from a “hold” rating to a “buy” rating and boosted their target price for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $251.00.

AbbVie Price Performance

NYSE:ABBV opened at $223.50 on Thursday. AbbVie has a 12 month low of $164.39 and a 12 month high of $244.81. The firm has a market capitalization of $395.01 billion, a PE ratio of 94.70, a price-to-earnings-growth ratio of 0.91 and a beta of 0.35. The business’s fifty day moving average price is $223.74 and its 200 day moving average price is $219.63.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the previous year, the business earned $2.16 EPS. AbbVie’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts anticipate that AbbVie will post 12.31 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Ellenbecker Investment Group lifted its stake in shares of AbbVie by 0.8% in the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after acquiring an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA raised its holdings in AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after purchasing an additional 45 shares in the last quarter. Matthew Goff Investment Advisor LLC boosted its holdings in AbbVie by 0.3% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock valued at $4,066,000 after purchasing an additional 45 shares in the last quarter. Centennial Wealth Advisory LLC increased its position in AbbVie by 2.2% during the 3rd quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after purchasing an additional 45 shares during the period. Finally, Eclectic Associates Inc. ADV raised its stake in shares of AbbVie by 0.8% during the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock worth $1,337,000 after buying an additional 45 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Morgan Stanley raised its price target to $270 and kept an “overweight” call, signaling institutional analyst conviction that AbbVie has double‑digit upside from current levels. Read More.
• Positive Sentiment: Company forecasts for full‑year 2026 profit came in above estimates, driven by strong sales of newer immunology drugs (Skyrizi, Rinvoq), supporting the case for continued top‑line and earnings growth. Read More.
• Positive Sentiment: Market commentary and some analysts view the post‑earnings pullback as a buying opportunity, pointing to institutional accumulation, durable cash flow, and a strong dividend as anchors for medium‑term returns. Read More.
• Positive Sentiment: New real‑world Rinvoq data from Japan bolsters the drug’s addressable market for ankylosing spondylitis and reinforces growth prospects for AbbVie’s immunology franchise. Read More.
• Neutral Sentiment: Management framed the earnings call around “new growth engines” — Skyrizi/Rinvoq and other launches taking the lead in driving growth, which supports the long‑term story but doesn’t eliminate near‑term volatility. Read More.
• Neutral Sentiment: Q4 results beat on revenue and showed strong margin/earnings leverage, confirming product momentum even as some segments face headwinds. Read More.
• Negative Sentiment: Shares initially gapped down after the print as investors focused on a softer-than‑expected Q1 EPS and revenue outlook despite the quarter’s beats — a classic near‑term reaction to guidance misses. Read More.
• Negative Sentiment: AbbVie set Q1 2026 EPS guidance at $2.97–$3.01 (vs. ~3.11 consensus) and gave revenue guidance below the street, creating short‑term uncertainty about the cadence of 2026 growth. Read More.
• Negative Sentiment: Broader coverage highlighted investor “angst” and a bifurcated reaction — bullish on medium‑term fundamentals but worried about near‑term comps and valuation — keeping volatility elevated. Read More.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.